Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02924883
Title A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy (KATE2)
Acronym KATE2
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ITA | GBR | ESP | DEU | CAN | AUS


No variant requirements are available.